The "Dietary Supplement Listing Act of 2026" aims to significantly improve transparency and the availability of information concerning dietary supplements marketed in the United States. It achieves this by amending the Federal Food, Drug, and Cosmetic Act to establish a mandatory listing requirement with the Food and Drug Administration (FDA). Under this bill, the responsible person (manufacturer, packer, or distributor) for each dietary supplement must submit comprehensive information to the Secretary. This includes the product's name, the responsible person's details, an electronic copy of the label, and a detailed list of all ingredients, including amounts per serving and proprietary blend components (which remain confidential). For dietary supplements already on the market by January 1, 2027, listing is required within 18 months of the bill's enactment, with a dietary supplement product listing number to appear on labels two years after enactment. New dietary supplements must be listed upon introduction into interstate commerce, with their listing number immediately included on the label. Responsible persons must also notify the FDA of discontinued products and update listings for any changes. The bill mandates the creation of a publicly available electronic database within two years of enactment, containing most of the submitted information, searchable by various fields. Certain sensitive information, such as specific business addresses and proprietary blend ingredient amounts, will remain confidential. Failure to comply with these listing requirements will render a dietary supplement misbranded . The legislation authorizes appropriations to support these activities and explicitly states that it does not grant the Secretary authority to require pre-market approval for dietary supplements, nor does it limit existing inspection authorities.